HK1063464A1 - Piperidine derivatives as nmda receptor antagonists - Google Patents
Piperidine derivatives as nmda receptor antagonistsInfo
- Publication number
- HK1063464A1 HK1063464A1 HK04106165.2A HK04106165A HK1063464A1 HK 1063464 A1 HK1063464 A1 HK 1063464A1 HK 04106165 A HK04106165 A HK 04106165A HK 1063464 A1 HK1063464 A1 HK 1063464A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- sub
- alkyl
- sup
- hydrogen
- groups
- Prior art date
Links
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 title 1
- 150000003053 piperidines Chemical class 0.000 title 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- -1 amino, mercapto Chemical class 0.000 abstract 2
- 125000002619 bicyclic group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 abstract 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000004419 alkynylene group Chemical group 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000002993 cycloalkylene group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000464 thioxo group Chemical group S=* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- AIDS & HIV (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU0103055A HU226978B1 (en) | 2001-07-24 | 2001-07-24 | New carboxylic acid amide compounds, process for their preparation and pharmaceutical compositions containing them and their use |
HU0202213A HU225905B1 (en) | 2002-07-10 | 2002-07-10 | Solid-supported parallel synthesis of new carboxylic acid amide derivatives |
PCT/HU2002/000071 WO2003010159A1 (en) | 2001-07-24 | 2002-07-23 | Piperidine derivatives as nmda receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1063464A1 true HK1063464A1 (en) | 2004-12-31 |
Family
ID=90001553
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK04106165.2A HK1063464A1 (en) | 2001-07-24 | 2004-08-17 | Piperidine derivatives as nmda receptor antagonists |
Country Status (33)
Country | Link |
---|---|
US (1) | US7435744B2 (et) |
EP (1) | EP1409477B1 (et) |
JP (1) | JP4322113B2 (et) |
KR (1) | KR100890676B1 (et) |
CN (1) | CN100413860C (et) |
AT (1) | ATE408611T1 (et) |
AU (1) | AU2002313566B2 (et) |
BG (1) | BG66441B1 (et) |
BR (1) | BR0211393A (et) |
CA (1) | CA2453383C (et) |
CO (1) | CO5560570A2 (et) |
CY (1) | CY1109401T1 (et) |
CZ (1) | CZ2004233A3 (et) |
DE (1) | DE60228969D1 (et) |
DK (1) | DK1409477T3 (et) |
EA (1) | EA010162B1 (et) |
EE (1) | EE05429B1 (et) |
ES (1) | ES2312603T3 (et) |
HK (1) | HK1063464A1 (et) |
HR (1) | HRP20040178B1 (et) |
IL (1) | IL159393A (et) |
IS (1) | IS7066A (et) |
MX (1) | MXPA04000737A (et) |
NO (1) | NO327099B1 (et) |
NZ (1) | NZ530055A (et) |
PL (1) | PL216636B1 (et) |
PT (1) | PT1409477E (et) |
RS (1) | RS50767B (et) |
SI (1) | SI1409477T1 (et) |
SK (1) | SK287726B6 (et) |
UA (1) | UA77684C2 (et) |
WO (1) | WO2003010159A1 (et) |
ZA (1) | ZA200400417B (et) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10210779A1 (de) * | 2002-03-12 | 2003-10-09 | Merck Patent Gmbh | Cyclische Amide |
PA8575901A1 (es) * | 2002-07-18 | 2004-07-20 | Pfizer Prod Inc | Derivados de piperidina novedosos |
ES2222833B1 (es) * | 2003-07-30 | 2006-03-01 | Laboratorios Del Dr. Esteve, S.A. | Compuestos piperidinicos 1,4-disustituidos, su preparacion y su uso como medicamentos. |
AU2004270733B2 (en) | 2003-09-11 | 2011-05-19 | Itherx Pharma, Inc. | Cytokine inhibitors |
WO2005030720A1 (ja) * | 2003-09-25 | 2005-04-07 | Shionogi & Co., Ltd. | Nmda受容体拮抗作用を有するピペリジン誘導体 |
US20050182061A1 (en) * | 2003-10-02 | 2005-08-18 | Jeremy Green | Phthalimide compounds useful as protein kinase inhibitors |
HUP0401522A2 (en) * | 2004-07-29 | 2006-04-28 | Richter Gedeon Vegyeszet | New 4-benzylidene-piperidine derivatives, pharmaceutical compositions containing the same and process for their preparation |
HU227000B1 (en) * | 2004-07-29 | 2010-04-28 | Richter Gedeon Nyrt | Nmda receptor antagonist benzoyl urea derivatives, and pharmaceutical compositions containing them |
EP2520567A3 (en) * | 2006-02-23 | 2012-12-12 | Shionogi & Co., Ltd. | Nitrogen-containing heterocycle derivatives substituted with cyclic group |
HUP0600809A3 (en) * | 2006-10-27 | 2008-09-29 | Richter Gedeon Nyrt | New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them |
HUP0600810A3 (en) * | 2006-10-27 | 2008-09-29 | Richter Gedeon Nyrt | New sulfonamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them |
HUP0600808A3 (en) * | 2006-10-27 | 2008-09-29 | Richter Gedeon Nyrt | New benzamide derivatives as bradykinin antagonists, process for their preparation and pharmaceutical compositions containing them |
EP1918281A1 (en) * | 2006-11-02 | 2008-05-07 | Laboratorios del Dr. Esteve S.A. | Phenylamino-substituted piperidine compounds, their preparation and use as medicaments |
JP5379692B2 (ja) | 2006-11-09 | 2013-12-25 | プロビオドルグ エージー | 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての3−ヒドロキシ−1,5−ジヒドロ−ピロール−2−オン誘導体 |
ATE554085T1 (de) | 2006-11-30 | 2012-05-15 | Probiodrug Ag | Neue inhibitoren von glutaminylcyclase |
NZ579310A (en) | 2007-03-01 | 2012-03-30 | Probiodrug Ag | Use of glutaminyl cyclase inhibitors for the treatment of mild cognitive impairment and diagnostic purposes thereof |
DK2142514T3 (da) | 2007-04-18 | 2015-03-23 | Probiodrug Ag | Thioureaderivater som glutaminylcyclase-inhibitorer |
EP2184272A4 (en) * | 2007-08-21 | 2011-11-09 | Shionogi & Co | PIPERAZINE DERIVATIVE |
DE102007047737A1 (de) * | 2007-10-05 | 2009-04-30 | Merck Patent Gmbh | Piperidin- und Piperazinderivate |
US20100298299A1 (en) * | 2007-10-27 | 2010-11-25 | Istvan Vago | non-peptide derivatives as bradykinin b1 antagonists |
AU2009268631A1 (en) * | 2008-07-08 | 2010-01-14 | Richter Gedeon Nyrt | Novel crystalline form of 2-[4(4-fluoro-benzyl)-piperidine-1-yl]-2-oxo-n-(2-oxo-2,3-dihydro-benzoxazol-6-yl)-acetamide |
US20100048629A1 (en) * | 2008-08-21 | 2010-02-25 | Allyson Gage | Methods for treating neuropathic pain |
AU2009282822A1 (en) * | 2008-08-21 | 2010-02-25 | Richter Gedeon Nyrt. | Methods for treating CNS disorders |
WO2010068794A2 (en) | 2008-12-10 | 2010-06-17 | The General Hospital Corporation | Hif inhibitors and use thereof |
HUP0900130A3 (en) | 2009-03-03 | 2012-02-28 | Richter Gedeon Nyrt | Novel crystalline hydrate, amorphous and polymorphic forms of dihydro-benzoxazole-6-yl-acetamide derivative and processes for their preparation |
US8486940B2 (en) | 2009-09-11 | 2013-07-16 | Probiodrug Ag | Inhibitors |
EP2512241A4 (en) * | 2009-12-15 | 2013-04-03 | Neurop Inc | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISEASES |
MX2012008721A (es) | 2010-02-16 | 2012-08-17 | Pfizer | (r)-4-((4-((4-(tetrahidrofuran-3-iloxi)benzo[d]isoxazol-3-iloxi)m etil) tetrahidro-2h-piran-4-ol, un agonista pacial de receptores 5-ht4. |
EP2542549B1 (en) | 2010-03-03 | 2016-05-11 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
BR112012022478B1 (pt) | 2010-03-10 | 2021-09-21 | Probiodrug Ag | Inibidores heterocíclicos de glutaminil ciclase (qc, ec 2.3.2.5), seu processo de preparação, e composição farmacêutica |
US8541596B2 (en) | 2010-04-21 | 2013-09-24 | Probiodrug Ag | Inhibitors |
HUP1000424A2 (en) | 2010-08-11 | 2012-05-02 | Richter Gedeon Nyrt | Use of radiprodil in attention deficit hyperactivity disorder |
US8530670B2 (en) | 2011-03-16 | 2013-09-10 | Probiodrug Ag | Inhibitors |
DK2921492T3 (en) * | 2011-12-27 | 2017-12-11 | Bayer Ip Gmbh | HETEROARYLPIPERIDINE AND ¿PIPERAZINE DERIVATIVES |
ES2627541T3 (es) | 2012-04-20 | 2017-07-28 | Ucb Pharma, S.A. | Métodos para tratar la enfermedad de Parkinson |
WO2014127256A1 (en) * | 2013-02-18 | 2014-08-21 | The Trustees Of Columbia University In The City Of New York | Kappa opioid receptor selective compounds |
UY36390A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
EP3215141A4 (en) * | 2014-11-05 | 2018-06-06 | Flexus Biosciences, Inc. | Immunoregulatory agents |
WO2017053769A1 (en) * | 2015-09-25 | 2017-03-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Triazole derivatives as p2y14 receptor antagonists |
ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
WO2019110703A1 (en) | 2017-12-08 | 2019-06-13 | Boehringer Ingelheim International Gmbh | Imidazopyridine derivatives and the use thereof as medicament |
WO2019115586A1 (en) * | 2017-12-12 | 2019-06-20 | Phenex Discovery Verwaltungs-GmbH | Oxalamides as modulators of indoleamine 2,3-dioxygenase |
AU2019362330B2 (en) * | 2018-10-17 | 2024-03-28 | Boehringer Ingelheim International Gmbh | 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament |
EP3866854B1 (en) | 2018-10-17 | 2022-08-10 | Boehringer Ingelheim International GmbH | 4-pyridinylmethyl-morpholine derivatives and the use thereof as medicament |
CN112888684B (zh) * | 2018-10-17 | 2023-10-10 | 勃林格殷格翰国际有限公司 | 4-嘧啶-5-基甲基-吗啉衍生物及其作为药物的用途 |
US11376258B2 (en) | 2019-06-04 | 2022-07-05 | Boehringer Ingelheim International Gmbh | Purine derivatives and the use thereof as medicament |
CN113234036B (zh) * | 2021-05-12 | 2023-07-14 | 斯莱普泰(上海)生物医药科技有限公司 | Nmda受体拮抗剂及其用途 |
MX2024001744A (es) | 2021-08-06 | 2024-04-23 | Grin Therapeutics Inc | Formulaciones de radiprodil. |
CN114163388A (zh) * | 2021-12-15 | 2022-03-11 | 陕西汉江药业集团股份有限公司 | 芬苯达唑中的杂质i、杂质ⅱ和杂质ⅲ的制备方法 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE254999C (et) | ||||
US2324123A (en) * | 1941-07-08 | 1943-07-13 | Eastman Kodak Co | Fog inhibitor for photographic developers |
US3260723A (en) * | 1963-08-27 | 1966-07-12 | Parke Davis & Co | 4-phenoxy piperidines; alpha4-phenoxy piperideines |
NL6501323A (et) | 1965-02-02 | 1966-08-03 | ||
US3632767A (en) * | 1968-02-12 | 1972-01-04 | Mallinckrodt Chemical Works | Treatment of depression with 4-substituted piperidines |
AU639529B2 (en) | 1987-03-04 | 1993-07-29 | Higuchi, Yoshinari | Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives |
SK232890A3 (en) | 1989-05-17 | 1998-11-04 | Pfizer | 2-piperidino and 2-pyrrolidino-1-alkanols derivatives and preparation method thereof |
FR2672286B1 (fr) * | 1991-01-31 | 1994-11-18 | Synthelabo | Derives de 1-(4-chlorophenyl)-2-[4-(phenylmethyl)piperidin-1-yl]ethanol, leur preparation et leur application en therapeutique. |
US5436255A (en) * | 1992-07-23 | 1995-07-25 | Pfizer Inc. | Method of treating diseases susceptable to treatment by blocking NMDA-receptors |
TW281670B (et) * | 1993-09-02 | 1996-07-21 | Hoffmann La Roche | |
ZA9610745B (en) * | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
ZA9610738B (en) * | 1995-12-22 | 1997-06-24 | Warner Lambert Co | Subtype selective nmda receptor ligands and the use thereof |
ZA9610736B (en) | 1995-12-22 | 1997-06-27 | Warner Lambert Co | 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists |
WO1997023202A1 (en) | 1995-12-22 | 1997-07-03 | STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of THE OREGON HEALTH SCIENCES UNIVERSITYA ND THE UNIVERSITY OF OREGON, EUGENE OREGON | Subtype-selective nmda receptor ligands and the use thereof |
ZA9610741B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
TW498067B (en) * | 1996-07-19 | 2002-08-11 | Hoffmann La Roche | 4-hydroxy-piperidine derivatives |
DE19643790A1 (de) | 1996-10-30 | 1998-05-07 | Merck Patent Gmbh | Benzoxazol-Derivat |
JP2000510870A (ja) * | 1997-02-14 | 2000-08-22 | バイエル・コーポレーシヨン | Npy5受容体アンタゴニストとしてのアミド類 |
US6048900A (en) * | 1998-02-13 | 2000-04-11 | Bayer Corporation | Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists |
HUP0004900A3 (en) | 1997-10-24 | 2002-03-28 | Warner Lambert Co | Pharmaceutical compositions for treating disease-related or drug-induced dyskinesias containing piperidine derivatives as nmda receptor antagonist as active ingredient |
PE20000728A1 (es) | 1998-06-26 | 2000-08-21 | Cocensys Inc | Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda |
AU1808100A (en) | 1998-10-28 | 2000-05-15 | Vitaly V. Romanenko | Electrodynamic particle size analyzer |
US6399631B1 (en) * | 1999-07-23 | 2002-06-04 | Pfizer Inc. | Carbazole neuropeptide Y5 antagonists |
US6369076B1 (en) | 1999-10-29 | 2002-04-09 | Merck & Co. Inc. | 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists |
EP1235572A2 (en) | 1999-10-29 | 2002-09-04 | MERCK SHARP & DOHME LTD. | Method to treat pain utilizing benzimidazole nmda/nr2b antagonists |
US6291499B1 (en) | 1999-10-29 | 2001-09-18 | Merck & Co., Inc. | 2-cyclohexyl benzimidazole NMDA/NR2B antagonists |
US6476041B1 (en) | 1999-10-29 | 2002-11-05 | Merck & Co., Inc. | 1,4 substituted piperidinyl NMDA/NR2B antagonists |
US6432976B1 (en) | 1999-10-29 | 2002-08-13 | Merck & Co., Inc. | 8-aza-bicyclo[3.2.1]octane NMDA/NR2B antagonists |
US6316474B1 (en) | 1999-10-29 | 2001-11-13 | Merck & Co., Inc. | 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists |
US6489477B1 (en) | 1999-10-29 | 2002-12-03 | Merck & Co., Inc. | 2-aza-bicyclo[2.2.2]octane NMDA/NR2B antigonists |
-
2002
- 2002-07-23 MX MXPA04000737A patent/MXPA04000737A/es active IP Right Grant
- 2002-07-23 EE EEP200400058A patent/EE05429B1/et unknown
- 2002-07-23 WO PCT/HU2002/000071 patent/WO2003010159A1/en active IP Right Grant
- 2002-07-23 DE DE60228969T patent/DE60228969D1/de not_active Expired - Lifetime
- 2002-07-23 CA CA2453383A patent/CA2453383C/en not_active Expired - Lifetime
- 2002-07-23 ES ES02753161T patent/ES2312603T3/es not_active Expired - Lifetime
- 2002-07-23 PL PL367259A patent/PL216636B1/pl unknown
- 2002-07-23 EP EP02753161A patent/EP1409477B1/en not_active Expired - Lifetime
- 2002-07-23 KR KR1020047001042A patent/KR100890676B1/ko not_active IP Right Cessation
- 2002-07-23 CZ CZ2004233A patent/CZ2004233A3/cs unknown
- 2002-07-23 NZ NZ530055A patent/NZ530055A/en not_active IP Right Cessation
- 2002-07-23 JP JP2003515518A patent/JP4322113B2/ja not_active Expired - Lifetime
- 2002-07-23 DK DK02753161T patent/DK1409477T3/da active
- 2002-07-23 SI SI200230752T patent/SI1409477T1/sl unknown
- 2002-07-23 SK SK102-2004A patent/SK287726B6/sk not_active IP Right Cessation
- 2002-07-23 PT PT02753161T patent/PT1409477E/pt unknown
- 2002-07-23 IL IL159393A patent/IL159393A/en active IP Right Grant
- 2002-07-23 EA EA200400213A patent/EA010162B1/ru not_active IP Right Cessation
- 2002-07-23 CN CNB028142349A patent/CN100413860C/zh not_active Expired - Lifetime
- 2002-07-23 AU AU2002313566A patent/AU2002313566B2/en not_active Expired
- 2002-07-23 AT AT02753161T patent/ATE408611T1/de active
- 2002-07-23 BR BR0211393-7A patent/BR0211393A/pt not_active IP Right Cessation
- 2002-07-23 RS YUP-1039/03A patent/RS50767B/sr unknown
-
2003
- 2003-12-05 IS IS7066A patent/IS7066A/is unknown
-
2004
- 2004-01-20 UA UA2004021342A patent/UA77684C2/uk unknown
- 2004-01-20 ZA ZA2004/00417A patent/ZA200400417B/en unknown
- 2004-01-21 US US10/761,940 patent/US7435744B2/en not_active Expired - Lifetime
- 2004-01-23 NO NO20040307A patent/NO327099B1/no not_active IP Right Cessation
- 2004-02-20 BG BG108592A patent/BG66441B1/bg unknown
- 2004-02-23 HR HRP20040178AA patent/HRP20040178B1/hr not_active IP Right Cessation
- 2004-02-23 CO CO04015496A patent/CO5560570A2/es active IP Right Grant
- 2004-08-17 HK HK04106165.2A patent/HK1063464A1/xx not_active IP Right Cessation
-
2008
- 2008-12-03 CY CY20081101405T patent/CY1109401T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60228969D1 (et) | ||
NO970501L (no) | Substituerte kinazolinderivater | |
CA2252907A1 (en) | Novel 2,3 disubstituted-4(3h)-quinazolinones | |
NZ503912A (en) | Piperidinylaminomethyl trifluoromethyl cyclic ether compounds and their use as substance P antagonists | |
DE69401716D1 (de) | Imidazo [1,2-a] pyrasin-4-on-derivate welche als ampa und nmda receptor antagonisten dienen | |
NO20013684L (no) | Substituerte fenetylaminderivater | |
HUP0302193A2 (hu) | 1,4-Diazabiciklo[3.2.2]nonán-benzoxazol,-benzotiazol és -benzimidazol-származékok, előállításuk és ezeket tartalmazó gyógyszerkészítmények | |
FI964463A0 (fi) | Bisykliset amidiinijohdannaiset typpioksidinsyntetaasin inhibiittoreina | |
AUPP150098A0 (en) | Benzamide derivatives | |
PT1044186E (pt) | Composto 2-benzilamino-2-fenil-acetamida substituidos | |
CA2210913A1 (en) | Antipsychotic 4-(1h-indolyl-1-yl)-1-substituted piperidine derivatives | |
ATE270289T1 (de) | Heteroaryloxypropanolamine als beta3- adrenergischer rezeptor-agonisten | |
TW429253B (en) | Novel pyrazole compounds | |
CA2285535A1 (en) | Benzimidazole derivative for treating allergy-related disease | |
DE59604901D1 (de) | Carbamoylcarbonsäureamide | |
EP1319656A4 (en) | NEW METHOD FOR PRODUCING A CHINOLON CARBONIC ACID | |
EA200400470A1 (ru) | Замещенные производные алкиламинопиридазинона, способ их получения и содержащие их фармацевтические композиции | |
ZA956579B (en) | Saccharin derivatives. | |
CA2245484A1 (en) | Novel urea derivatives | |
TW429147B (en) | Pharmaceutical composition for the treatment of CNS disorders | |
TW325460B (en) | Imidic acid derivatives | |
DK0531119T3 (da) | N,N,N-trisubstituerede 5-bis-aminomethylen-1,3-dioxan-4,6-dioner som inhibitorer af acyl-CoA: cholesterol-acyltransferase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CHRG | Changes in the register |
Free format text: CORRECTION OF THE NAME OF THE INVENTOR FROM VA KOVACSNE BOZO TO BOZO EVA |
|
PE | Patent expired |
Effective date: 20220722 |